WASHINGTON (Reuters) -The Food and Drug Administration is expected to authorize the use of the Pfizer (NYSE:PFE) COVID-19... By Hyonhee Shin SEOUL (Reuters) - One dose of COVID-19 vaccines from ...

Next: Get access to a new market-moving chart every ... company’s COVID-19 vaccines due to reduced market demand. In addition, write-downs by BioNTech’s collaboration partner Pfizer Inc ...

Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

Britain hit covid hard. Its lockdown was longer than those of most of its peers, totalling 120 days of national “stay at home” orders. It had one of the bigger fiscal responses. Its health service ...

with Pfizer's TTM R&D spending above $10 billion. The R&D spike of 2021-2023 should not mislead readers, as the company invested heavily in developing the COVID-19 vaccine, which was kind of a ...

The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 5 are puts, totaling $799,839, and 22 are calls, amounting to ...

Uncle Sam’s abiding ambivalence about having close ties with corporate America is getting some fresh, albeit unwelcome, ...

In an era where misinformation can spread rapidly online, parents are often left grappling with conflicting advice about ...

To Tod Dillard, COVID-19 was no big deal. Until it nearly killed him ... and I joyfully welcomed the arrival of vaccines developed by companies such as Pfizer, Moderna and Johnson & Johnson. “The ...

Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...